Navigation Links
Sosei Announces Deal With UK Biotech Company
Date:10/14/2009

TOKYO, Japan, October 14 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the assignment of the drug discovery programme, SD281 and its analogues, to Biocopea Limited, a UK biotechnology company and subsidiary of PepTcell Limited. These compounds, based on a metabolite of a well-known drug, were shown by Sosei to have pronounced anti-inflammatory properties. Sosei had positioned the compounds for intervention in inflammatory diseases such as Inflammatory Bowel Disease (IBD). Biocopea intends to develop the portfolio of compounds further using its specialized chemical design, specific disease models and immunology expertise.

The deal means that a promising class of new chemical entities with a long remaining patent life can be taken forward by a partner committed to the development of new therapies for a variety of immune diseases. Under the terms of the assignment, Sosei will receive payments when the compounds are commercialized by Biocopea or its partners.

Notes for Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

About Biocopea

Biocopea is focussed upon the identification and exploitation of novel biology from existing drug templates. It is 75% owned by PepTcell Limited, a biotechnology company with the aim of converting theoretical concepts into novel analytical tools and c
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sosei Announces Filing of NDA for SOH-075 (NorLevo(R)) in Japan
2. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
3. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
4. Sosei Announces Outcome of Strategy Review
5. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
6. Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care
7. Health Robotics Announces First Five i.v.STATION(TM) Robot Shipments and Receipt of 3L/3T Innovation Award
8. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
10. Nanogea Announces New Scientific Advisory Board Members
11. CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, 2015 ... that Roger Jeffs , Ph.D., President and Co-Chief Executive ... on the company,s business at the Deutsche Bank 40 th ... . The presentation will take place on ... can be accessed via a live webcast on the United ...
(Date:4/30/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, announced plans to ... 2015 on May 7, 2015 after the close of ... host a conference call at 4:30 p.m. Eastern Time ... financial results. During the conference call, material information concerning ...
(Date:4/30/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) reported total ... were $4.4 million, compared to $8.0 million during the same ... quarter was $8.9 million, or $0.23 per basic and diluted ... same period in 2014, of $8.7 million, or $0.27 per ... cash, cash equivalents and investments totaled $117.5 million. , ...
(Date:4/30/2015)... April 30, 2015 Nitto Avecia, ... announces its increased capacity and production capability to ... client variety and service fulfillment continues to drive ... improve process throughput capacities. , In ... installed downstream process equipment at its Milford, MA ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... Intercell AG (VSE: ICLL) today announced that it ... U.S. Food and Drug Administration,s (FDA) approval of IXIARO(R), ... (JE). The initial target for use of Intercell,s vaccine ... U.S. market - will be adult travelers and military ...
... DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or ... financial results for 2008. DOR,s revenues for 2008 were ... The increase was due primarily to progress with ... of certain research and development milestones with our subcontractors. ...
... Va., March 31 - Innocoll, Inc. announced that its ... application for its CollaRx(TM) Lidocaine Sponge for the management ... year 13 million patients worldwide suffer from chronic wounds ... 35 percent of all chronic wounds do not ...
Cached Biology Technology:Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 2Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 5Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge 2
(Date:4/1/2015)... 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces the second ... is underway to early access pre-order customers. ... at retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, ... was accepted at all outlets and very easy to ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... Institute and MIT have engineered yeast that can improve ... component to making biofuels a significant part of the ... additive to improve gasoline combustibility, ethanol is often touted ... crisis. But there are significant obstacles to producing ethanol. ...
... manipulate the brain's perception of jaw movement while words ... importance of non-auditory sensory cues in the brain's control ... and David Ostry of McGill University and appear in ... published by Cell Press. , When we speak, ...
... Institute have identified a novel biomarker for brain tumors ... play when the tumor spreads or comes back after ... cerebrospinal fluid of patients with malignant astrocytoma and mediates ... of Clinical Cancer Research. , The biomarker, ...
Cached Biology News:Engineered yeast speeds ethanol production 2Sensory feedback during speech: The brain attunes to more than just sound 2Newly identified biomarker detects and regulates spread of brain tumors 2
... The new MALDI O-TOF creates a ... on an orthogonal platform that has been ... the University of Manitoba. , As the ... orthogonal design and collisional cooling, the prOTOF ...
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
37-1A9...
Biology Products: